Chemclin Diagnostics Co., Ltd. (SHA:688468)

China flag China · Delayed Price · Currency is CNY
7.68
+0.22 (2.95%)
Mar 10, 2026, 2:54 PM CST
-2.78%
Market Cap 2.94B
Revenue (ttm) 353.32M
Net Income (ttm) 56.49M
Shares Out 394.59M
EPS (ttm) 0.14
PE Ratio 53.94
Forward PE n/a
Dividend 0.13 (1.68%)
Ex-Dividend Date Jun 13, 2025
Volume 3,970,078
Average Volume 4,029,289
Open 7.51
Previous Close 7.46
Day's Range 7.50 - 7.69
52-Week Range 6.04 - 9.12
Beta 0.08
RSI 40.29
Earnings Date Apr 29, 2026

About Chemclin Diagnostics

Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, hepatitis E, etc.; and detection of tumor markers, thyroid hormones, reproductive endocrine ho... [Read more]

Sector Healthcare
Founded 2007
Employees 606
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688468
Full Company Profile

Financial Performance

In 2024, Chemclin Diagnostics's revenue was 436.29 million, a decrease of -2.03% compared to the previous year's 445.34 million. Earnings were 127.07 million, a decrease of -13.77%.

Financial Statements

News

There is no news available yet.